Intranasal insulin improves cognition and modulates beta-amyloid in early AD

• Published in: Neurology Vol. 70; no. 6; p. 440
• Main Authors: Reger, M A, Watson, G S, Green, P S, Wilkinson, C W, Baker, L D, Cholerton, B, Fishel, M A, Plymate, S R, Breitner, J C S, DeGroodt, W, Mehta, P, Craft, S
• Format: Journal Article
• Language: English
• Published: United States 05.02.2008
• Subjects: Administration, Intranasal; Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Alzheimer Disease - physiopathology; Alzheimer Disease - psychology; Amyloid beta-Peptides - blood; Amyloid beta-Peptides - drug effects; Attention - drug effects; Attention - physiology; Brain - drug effects; Brain - metabolism; Brain - physiopathology; Cognition Disorders - drug therapy; Cognition Disorders - etiology; Cognition Disorders - physiopathology; Disease Progression; Humans; Insulin - administration & dosage; Neuroprotective Agents - administration & dosage; Neuropsychological Tests; Peptide Fragments - blood; Peptide Fragments - drug effects; Pilot Projects; Plaque, Amyloid - drug effects; Plaque, Amyloid - metabolism; Treatment Outcome; Verbal Behavior - drug effects; Verbal Behavior - physiology

Reduced brain insulin signaling and low CSF-to-plasma insulin ratios have been observed in patients with Alzheimer disease (AD). Furthermore, intracerebroventricular or IV insulin administration improve memory, alter evoked potentials, and modulate neurotransmitters, possibly by augmenting low brain...